CRLF2 and acute lymphoblastic leukemia: To better understand the coordinated CRLF2 signaling connections and how to disrupt them, we subjected the same BCP-ALL primary samples to pharmacologic inhibition using kinase inhibitors (KIs) targeting JAK/STAT (ruxolitinib), SRC/ABL (dasatinib), or PI3K/mTOR (NVP-BEZ235) pathways (as represented in Figure 2A).